52MO A randomized phase II trial of durvalumab and tremelIMUmab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with CHolangio- and gallbladdEr Carcinoma (IMMUCHEC).
Saved in:
| Title: | 52MO A randomized phase II trial of durvalumab and tremelIMUmab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with CHolangio- and gallbladdEr Carcinoma (IMMUCHEC). |
|---|---|
| Authors: | Vogel, A.1 (AUTHOR), Boeck, S.2 (AUTHOR), Waidmann, O.3 (AUTHOR), Bitzer, M.4 (AUTHOR), Wenzel, P.5 (AUTHOR), Belle, S.6 (AUTHOR), Springfeld, C.7 (AUTHOR), Schulze, K.8 (AUTHOR), Weinmann, A.9 (AUTHOR), Lindig, U.10 (AUTHOR), Trautwein, C.11 (AUTHOR), Dechow, T.12 (AUTHOR), Lammert, F.13 (AUTHOR), Plentz, R.14 (AUTHOR), Koehne, C-H.15 (AUTHOR), Kunzmann, V.16 (AUTHOR), Maenz, M.17 (AUTHOR), Kirstein, M.M.18 (AUTHOR), Saborowski, A.19 (AUTHOR) |
| Source: | Annals of Oncology. 2022 Supplement 7, Vol. 33, pS563-S563. 1p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 159076882 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: 52MO A randomized phase II trial of durvalumab and tremelIMUmab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with CHolangio- and gallbladdEr Carcinoma (IMMUCHEC). – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Vogel%2C+A%2E%22">Vogel, A.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Boeck%2C+S%2E%22">Boeck, S.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Waidmann%2C+O%2E%22">Waidmann, O.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bitzer%2C+M%2E%22">Bitzer, M.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wenzel%2C+P%2E%22">Wenzel, P.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Belle%2C+S%2E%22">Belle, S.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Springfeld%2C+C%2E%22">Springfeld, C.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Schulze%2C+K%2E%22">Schulze, K.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Weinmann%2C+A%2E%22">Weinmann, A.</searchLink><relatesTo>9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lindig%2C+U%2E%22">Lindig, U.</searchLink><relatesTo>10</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Trautwein%2C+C%2E%22">Trautwein, C.</searchLink><relatesTo>11</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Dechow%2C+T%2E%22">Dechow, T.</searchLink><relatesTo>12</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lammert%2C+F%2E%22">Lammert, F.</searchLink><relatesTo>13</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Plentz%2C+R%2E%22">Plentz, R.</searchLink><relatesTo>14</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Koehne%2C+C-H%2E%22">Koehne, C-H.</searchLink><relatesTo>15</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kunzmann%2C+V%2E%22">Kunzmann, V.</searchLink><relatesTo>16</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Maenz%2C+M%2E%22">Maenz, M.</searchLink><relatesTo>17</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kirstein%2C+M%2EM%2E%22">Kirstein, M.M.</searchLink><relatesTo>18</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Saborowski%2C+A%2E%22">Saborowski, A.</searchLink><relatesTo>19</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2022 Supplement 7, Vol. 33, pS563-S563. 1p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=159076882 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.annonc.2022.07.080 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 1 StartPage: S563 Titles: – TitleFull: 52MO A randomized phase II trial of durvalumab and tremelIMUmab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with CHolangio- and gallbladdEr Carcinoma (IMMUCHEC). Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Vogel, A. – PersonEntity: Name: NameFull: Boeck, S. – PersonEntity: Name: NameFull: Waidmann, O. – PersonEntity: Name: NameFull: Bitzer, M. – PersonEntity: Name: NameFull: Wenzel, P. – PersonEntity: Name: NameFull: Belle, S. – PersonEntity: Name: NameFull: Springfeld, C. – PersonEntity: Name: NameFull: Schulze, K. – PersonEntity: Name: NameFull: Weinmann, A. – PersonEntity: Name: NameFull: Lindig, U. – PersonEntity: Name: NameFull: Trautwein, C. – PersonEntity: Name: NameFull: Dechow, T. – PersonEntity: Name: NameFull: Lammert, F. – PersonEntity: Name: NameFull: Plentz, R. – PersonEntity: Name: NameFull: Koehne, C-H. – PersonEntity: Name: NameFull: Kunzmann, V. – PersonEntity: Name: NameFull: Maenz, M. – PersonEntity: Name: NameFull: Kirstein, M.M. – PersonEntity: Name: NameFull: Saborowski, A. IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 09 Text: 2022 Supplement 7 Type: published Y: 2022 Identifiers: – Type: issn-print Value: 09237534 Numbering: – Type: volume Value: 33 Titles: – TitleFull: Annals of Oncology Type: main |
| ResultId | 1 |
